Our results demonstrated that 3 μmol/L or lower concentrations of linsitinib alone did not affect the viability of EGFR-mutated NSCLC cell lines, irrespective of the AXL expression (Supplementary Fig. 10). This evidence concerns the gene EGFR and non-small cell lung carcinoma.